<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Causes and pathophysiology of high-output heart failure</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Causes and pathophysiology of high-output heart failure</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Causes and pathophysiology of high-output heart failure</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael M Givertz, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barry A Borlaug, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>While most patients with heart failure (HF), with either reduced or preserved ejection fraction, have low or normal cardiac output accompanied by elevated systemic vascular resistance, a minority of patients with HF present with a high-output state with low systemic vascular resistance.</p><p>This topic will discuss the causes and pathophysiology of high-output HF. Clinical manifestations, diagnosis, and management of high-output HF are discussed separately. (See  <a class="medical medical_review" href="/d/html/113041.html" rel="external">"Clinical manifestations, diagnosis, and management of high-output heart failure"</a>.)</p><p>The diagnosis and management of HF with reduced ejection fraction and HF with preserved ejection fraction are discussed separately. (See  <a class="medical medical_review" href="/d/html/3485.html" rel="external">"Determining the etiology and severity of heart failure or cardiomyopathy"</a> and  <a class="medical medical_review" href="/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a> and  <a class="medical medical_review" href="/d/html/3504.html" rel="external">"Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction"</a>.)</p><p class="headingAnchor" id="H1899628607"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>High-output HF is an uncommon type of HF. The prevalence of this disorder is uncertain, particularly since the potential contributory role of high-output syndromes to HF may not be appreciated in many cases. Although high-output states are uncommon as a sole cause of HF, they may more commonly contribute to HF in patients with underlying cardiovascular disease and reduced myocardial reserve. (See <a class="local">'Role of concurrent cardiac conditions'</a> below.)</p><p>In a Mayo Clinic series of 120 consecutive patients with high-output HF diagnosed between 2000 and 2014, the most common causes were obesity (31 percent), liver disease (22.5 percent), arteriovenous shunts (22.5 percent), lung disease (16 percent), and myeloproliferative disorders (8 percent) [<a href="#rid1">1</a>]. This study excluded patients with physiologic (eg, pregnancy, fever, infection), iatrogenic (pulmonary vasodilator or inotrope administration), or congenital causes of high output, as well as patients with severe anemia (hemoglobin &lt;8 mg/dL), hyperthyroidism, valvular heart disease, constrictive pericarditis, left ventricular systolic dysfunction (left ventricular ejection fraction &lt;45 percent), cardiomyopathy, or heart transplantation. </p><p>In a study from the National Readmission Database that included nearly 5.1 million encounters, 3897 hospitalizations with high-output HF were recorded [<a href="#rid2">2</a>]. The most common causes of high-output HF were pulmonary disease (19.8 percent), obesity (9.9 percent), sepsis (9.6 percent), cirrhosis (8.9 percent), myelodysplastic syndrome (7.9 percent), hyperthyroidism (5.5 percent), and sickle cell disease (3.3 percent).</p><p class="headingAnchor" id="H1981261847"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>High-output HF is characterized by elevated cardiac output, low systemic vascular resistance (due to peripheral vasodilation or arteriovenous shunting), and low arterial-venous oxygen content difference; some types are associated with increased oxygen consumption (reflecting increased metabolic demand). In the setting of high-output HF, the elevation in cardiac output is greater than that required to meet metabolic demand [<a href="#rid1">1</a>].</p><p>In high-output HF, low systemic vascular resistance results in borderline preserved or depressed systemic arterial blood pressure and elevated cardiac filling pressures [<a href="#rid1">1</a>]. Ineffective blood volume and pressure lead to activation of the sympathetic nervous system and renin-angiotensin-aldosterone axis and increased serum vasopressin (antidiuretic hormone) concentrations. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a rodent model of high-output HF, enhanced renal vascular responsiveness to angiotensin II influenced renal hemodynamics and tubular reabsorption and led to renal dysfunction [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a related preclinical model, chronic activation of catecholaminergic neurons of the rostral ventrolateral medulla promoted autonomic imbalance and cardiorespiratory dysfunction in high-output HF. This pathophysiology was reversed with inhibition of brainstem endoplasmic reticulum stress [<a href="#rid4">4</a>].</p><p></p><p>This neurohormonal activation results in increased renovascular resistance and reduced renal blood flow and glomerular filtration rate, with retention of salt and water [<a href="#rid5">5</a>]. Chronic volume overload gradually may cause ventricular enlargement, remodeling, and HF. Activation of neprilysin and the sodium-glucose co-transporter 2 have also been implicated in interstitial fibrosis and subsequent ventricular remodeling in high cardiac output states [<a href="#rid6">6</a>].</p><p>The conditions that provoke high-output HF are rarely the sole cause of HF. In most such patients, the high cardiac output provokes HF in the setting of reduced ventricular reserve (systolic and/or diastolic dysfunction) from some underlying cardiac problem. Thus, the presence of high-output HF should prompt a search for another underlying cardiovascular condition. (See <a class="local">'Role of concurrent cardiac conditions'</a> below and  <a class="medical medical_review" href="/d/html/113041.html" rel="external">"Clinical manifestations, diagnosis, and management of high-output heart failure", section on 'Diagnostic evaluation'</a>.)</p><p class="headingAnchor" id="H1590881010"><span class="h1">CAUSES AND THEIR MECHANISMS</span><span class="headingEndMark"> — </span>A number of conditions lead to an obligatory increase in cardiac output, which can precipitate HF in some patients [<a href="#rid1">1,7</a>]. While hemodynamic alterations are present across various etiologies, there are some differences among etiologies. In a series of 120 consecutive patients with high-output HF, oxygen consumption indexed to weight was highest and mixed venous oxygen content was lowest in the myeloproliferative disorder group [<a href="#rid1">1</a>]. The subgroup with liver disease had the lowest arterial-venous oxygen content difference and lowest systemic vascular resistance.</p><p>There are a variety of pathophysiologic processes that result in a high-output state. Some causes appear to have primarily peripheral vascular effects, while other causes may have metabolic effects or myocardial as well as peripheral vascular effects. The distinction between these categories is imperfect, since some causes are associated with combinations of peripheral vascular, metabolic, and myocardial effects (eg, hyperthyroidism). Peripheral vascular effects can have secondary effects on cardiac structure and function.</p><p>The prognosis of high-output HF is highly variable, as it is largely dependent upon the cause, underlying cardiovascular disease, and concurrent conditions. Overall, the mortality rate in patients with high-output HF is increased compared with controls without heart disease (eg, hazard ratio 3.4; 95% CI 1.6-7.6 compared with controls [<a href="#rid1">1</a>]). Compared with patients with HF with reduced ejection fraction, patients with high-output HF have a similar inpatient mortality rate (4.3 versus 5.2 percent; odds ratio [OR] 0.9, 95% CI 0.7-1.2) but lower 30-day readmission rate (5.7 versus 21.2 percent; OR 0.39, 95% CI 0.30-0.51) [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H3648838780"><span class="h2">Causes grouped by predominant mechanism</span></p><p class="headingAnchor" id="H1322620532"><span class="h3">Peripheral vascular effects</span><span class="headingEndMark"> — </span>The following conditions with largely peripheral vascular primary effects can lead to high-output HF. Peripheral vascular effects can lead to cardiac volume overload.</p><p class="headingAnchor" id="H949131210"><span class="h4">Obesity</span><span class="headingEndMark"> — </span>High-output HF in patients with obesity appears to be related to vasodilation, but the mechanism for vasodilation is unclear [<a href="#rid1">1</a>]. Although oxygen consumption is high in this setting, it is not elevated after adjustment for weight. The effects of obesity on the cardiovascular system may be exacerbated by pressure overload states such as hypertension [<a href="#rid8">8</a>]. Some data suggest that leptin may contribute to plasma volume expansion as well as eccentric ventricular dilatation and hypertrophy that is seen in high-output states [<a href="#rid9">9</a>]. It should also be noted that obesity is a key risk factor and distinct phenotype of HF with preserved ejection fraction, in which hemodynamic evaluation typically reveals elevated cardiac filling pressures with normal or reduced cardiac output (also known as "obesity phenotype of HFpEF") [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/3457.html" rel="external">"Pathophysiology of heart failure with preserved ejection fraction"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In metabolically healthy subjects, high body mass index is associated with increased risk of diastolic dysfunction [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with obesity (body mass index &gt;35 kg/m<sup>2</sup>) undergoing bariatric surgery, the presence of nonalcoholic steatohepatitis was associated with left ventricular concentric remodeling and hyperdynamic circulation [<a href="#rid12">12</a>].</p><p></p><p class="headingAnchor" id="H2224858461"><span class="h4">Arteriovenous fistula</span><span class="headingEndMark"> — </span>A large or multiple small systemic arteriovenous fistulas can cause high-output HF. A fistula can be congenital or acquired. Blood from a high-pressure artery is shunted via the arteriovenous fistula to a low-pressure vein, thus bypassing capillary beds and decreasing systemic vascular resistance. Compensatory increases in heart rate, stroke volume, and total plasma volume ensue to maintain systemic perfusion. Thus, the elevation in cardiac output associated with a fistula depends upon the size of the communication and the magnitude of the resultant reduction in systemic vascular resistance.</p><p>As described below, high-output HF in patients with chronic kidney disease most often results from an arteriovenous dialysis fistula and anemia (which is now less common due to the widespread use of erythropoietin) superimposed on underlying heart disease. Other renal etiologies include acquired intrarenal arteriovenous fistulas such as those arising as a complication following renal biopsy, renal cell carcinoma [<a href="#rid13">13</a>], and congenital renal arteriovenous malformation [<a href="#rid14">14,15</a>].</p><p class="headingAnchor" id="H2493289103"><span class="h5">Acquired</span><span class="headingEndMark"> — </span>Acquired fistulas may be caused by trauma [<a href="#rid16">16</a>], by a medical procedure (eg, surgically constructed arteriovenous access for hemodialysis or as a complication of a procedure), or by a highly vascular condition or tumor. Traumatic causes include bullet or knife wounds, especially in the thigh.</p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review of traumatic arteriovenous fistulas in 274 patients [<a href="#rid17">17</a>], the median age at presentation was 32 years and 90 percent were men. Stab wounds (43 percent) and gunshot wounds (32 percent) were the most frequent mechanism of injury; the most frequent locations were abdomen (31 percent), lower limb (29 percent), and neck (22 percent). In the 35 patients (13 percent) who presented with HF, independent predictors of HF were involvement of a large feeding artery and delayed presentation.</p><p></p><p>An aortocaval fistula may be caused by trauma or by spontaneous rupture of an aortic aneurysm [<a href="#rid18">18,19</a>].</p><p>Iatrogenic fistulas include surgically constructed arteriovenous fistulas used for access to the circulation in patients undergoing chronic hemodialysis [<a href="#rid20">20-22</a>]. An arteriovenous fistula can cause high-output HF and can also worsen pulmonary hypertension and cause right HF, as discussed separately [<a href="#rid23">23</a>]. Removal of unused arteriovenous fistulae following renal transplant may be beneficial in this setting [<a href="#rid24">24,25</a>]. For hemodialysis patients with HF, surgical revision of a high-flow arteriovenous fistula can reduce blood flow and improve cardiac function [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/d/html/1958.html" rel="external">"Evaluation and management of heart failure caused by hemodialysis arteriovenous access"</a> and  <a class="medical medical_review" href="/d/html/112442.html" rel="external">"Pulmonary hypertension in patients with end-stage kidney disease"</a>.)</p><p>A renal arteriovenous fistula is a complication of renal biopsy, although a symptomatic fistula causing high-output HF is rare. Other cases of iatrogenic arteriovenous fistulas associated with high-output failure include an iliac arteriovenous fistula after spinal surgery [<a href="#rid16">16</a>] or abdominal surgery [<a href="#rid27">27</a>] and high-output failure following transjugular intrahepatic portosystemic shunting (TIPS) [<a href="#rid28">28</a>]. In a prospective study of 15 portal hypertensive patients, hyperdynamic circulation worsened immediately after TIPS, with a progressive adaptation over two months [<a href="#rid29">29</a>].</p><p>Arterial puncture for cardiac catheterization is an uncommon iatrogenic cause of arteriovenous fistula with an incidence of less than 1 percent of catheterizations with a transfemoral approach [<a href="#rid30">30,31</a>] and less than 0.1 percent using a transradial or transulnar approach [<a href="#rid32">32,33</a>]. High-output HF is a rare sequela of an arteriovenous fistula from cardiac catheterization with a clinical presentation ranging from two days to several months postcatheterization [<a href="#rid34">34</a>].</p><p>Skeletal disorders such as osteitis deformans (Paget disease) [<a href="#rid35">35</a>], multiple myeloma [<a href="#rid36">36-38</a>], and polyostotic fibrous dysplasia (McCune-Albright syndrome) have been identified as causes of high-output HF. Multiple minute arteriovenous fistulas in the bony lesions may cause high-output HF [<a href="#rid38">38</a>]. Extensive bone involvement (more than 20 percent of the skeleton) is required to increase the cardiac output to the point at which it may contribute to high-output problems. An additional factor for the increase in cardiac output in Paget disease may be increased cutaneous blood flow resulting from local heat production by the increased metabolic activity of affected bone. There appears to be a linear relationship between the amount of skeletal involvement and cardiac index in patients with this disease. In one study, the subgroup of patients with more extensive skeletal involvement had lower peripheral vascular resistance, higher stroke volume, and greater hydroxyproline excretion (a marker of bone turnover) [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/5601.html" rel="external">"Clinical manifestations and diagnosis of Paget disease of bone"</a> and  <a class="medical medical_review" href="/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5812.html" rel="external">"Definition, etiology, and evaluation of precocious puberty", section on 'McCune-Albright syndrome'</a>.)</p><p>High-output HF with acquired arteriovenous fistula(s) may also be caused by a highly vascular condition or tumor such as Paget disease, Wilms' tumor [<a href="#rid40">40</a>], renal cell carcinoma [<a href="#rid13">13,41,42</a>], uterine leiomyomatosis [<a href="#rid43">43</a>], or giant placental chorioangioma [<a href="#rid44">44</a>]. Clinical manifestations of these conditions are discussed further separately. (See  <a class="medical medical_review" href="/d/html/6249.html" rel="external">"Presentation, diagnosis, and staging of Wilms tumor"</a> and  <a class="medical medical_review" href="/d/html/2983.html" rel="external">"Clinical manifestations, evaluation, and staging of renal cell carcinoma"</a>.)</p><p class="headingAnchor" id="H1886827248"><span class="h5">Congenital</span><span class="headingEndMark"> — </span>Congenital arteriovenous fistulas range from small cutaneous hemangiomas to large channel communications that can distort a limb [<a href="#rid45">45</a>]. A minority of patients with congenital fistulas have giant or multiple hemangiomas, which cause HF [<a href="#rid46">46,47</a>]. (See  <a class="medical medical_review" href="/d/html/3594.html" rel="external">"Hepatic hemangioma"</a> and  <a class="medical medical_review" href="/d/html/13727.html" rel="external">"Congenital hemangiomas: Rapidly involuting congenital hemangioma (RICH), noninvoluting congenital hemangioma (NICH), and partially involuting congenital hemangioma (PICH)"</a> and  <a class="medical medical_review" href="/d/html/5794.html" rel="external">"Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications"</a>.)</p><p>Hepatic hemangiomas are typically found incidentally, with larger lesions (4 cm) more likely to present with symptoms such as abdominal pain, right upper quadrant discomfort, or fullness. Hepatic hemangiomas rarely cause high-output failure either in the setting of innumerable hemangiomas (known as hepatic hemangiomatosis) or in the setting of a giant hemangioma. Cutaneous hemangiomas may be a marker for hepatic hemangiomas. (See  <a class="medical medical_review" href="/d/html/3594.html" rel="external">"Hepatic hemangioma"</a>.)</p><p>Hereditary hemorrhagic telangiectasia (HHT or Osler-Weber-Rendu disease) is characterized by hemorrhagic telangiectasias involving the mucous membranes (causing epistaxis and gastrointestinal bleeding) and skin (eg, lips, fingertips). In approximately 15 percent of affected individuals, arteriovenous malformations occur in the lung and may be associated with massive hemoptysis [<a href="#rid48">48,49</a>]. Some patients with hepatic involvement develop clinically significant arteriovenous shunts and high-output failure [<a href="#rid50">50-54</a>]. In some patients, high-output HF is the first manifestation of the disease [<a href="#rid54">54</a>], while in a subgroup of patients, clinical HF may be exacerbated by hypoxemia caused by concomitant pulmonary arteriovenous shunts [<a href="#rid55">55</a>]. Additional clinical manifestations include unexplained hematuria, hemoptysis, or family history of bleeding. (See  <a class="medical medical_review" href="/d/html/1345.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)"</a>.)</p><p>Giant cutaneous hemangiomas can also promote the development of high-output failure [<a href="#rid56">56,57</a>]. Hemangiomas are the most common tumors of infancy and seldom cause more than a cosmetic problem. Fifty percent of cutaneous lesions are present at birth; the remainder usually surface by two months of age. In rare cases, high-flow arteriovenous shunting in giant or multiple cutaneous hemangiomas can lead to the development of high-output failure [<a href="#rid46">46,56,58,59</a>]. (See  <a class="medical medical_review" href="/d/html/5794.html" rel="external">"Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications"</a>.)</p><p class="headingAnchor" id="H2821369272"><span class="h4">Cirrhosis</span><span class="headingEndMark"> — </span>Cirrhosis is associated with progressive systemic vasodilation (particularly splanchnic) and the development of intrahepatic or mesenteric arteriovenous shunts which cause increased cardiac output and low blood pressure. In a study of patients prior to liver transplantation, cirrhosis was associated with reductions in end-systolic elastance, arterial elastance, and ventriculoarterial coupling [<a href="#rid60">60</a>]. Others have shown elevated B-type natriuretic peptide levels [<a href="#rid61">61</a>]. Signs of reduced tissue perfusion include low urinary sodium excretion and increased plasma levels of the "hypovolemic" hormones renin, aldosterone, and vasopressin [<a href="#rid62">62-64</a>]. Intrapulmonary arteriovenous shunting is also observed in some patients [<a href="#rid65">65</a>]. The development of cardiac failure is insidious in these patients [<a href="#rid66">66</a>], but most die from hepatic failure prior to symptomatic heart disease. (See  <a class="medical medical_review" href="/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'Complications of portal hypertension'</a> and  <a class="medical medical_review" href="/d/html/2326.html" rel="external">"Hyponatremia in patients with cirrhosis", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H3763852197"><span class="h4">Erythroderma</span><span class="headingEndMark"> — </span>Erythroderma is a clinical presentation of a wide range of cutaneous and systemic diseases (including psoriasis and drug hypersensitivity reactions). The elevated cardiac output results from substantial cutaneous dilatation and an increase in blood flow to the skin. Peripheral vasodilation associated with shunting of blood flow through the skin may result in high-output HF. (See  <a class="medical medical_review" href="/d/html/13659.html" rel="external">"Erythroderma in adults"</a>.)</p><p class="headingAnchor" id="H3231250366"><span class="h4">Carcinoid syndrome</span><span class="headingEndMark"> — </span>High-output HF (with low systemic vascular resistance and high cardiac output) is an atypical cardiovascular manifestation of carcinoid syndrome, which more commonly causes HF via right heart valve fibrosis [<a href="#rid67">67,68</a>]. (See  <a class="medical medical_review" href="/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome"</a> and  <a class="medical medical_review" href="/d/html/8135.html" rel="external">"Carcinoid heart disease"</a>.)</p><p class="headingAnchor" id="H3067750340"><span class="h3">Metabolic effects</span><span class="headingEndMark"> — </span>The following conditions result in increased metabolic demand that may drive increases in cardiac output:</p><p class="headingAnchor" id="H1337040532"><span class="h4">Myeloproliferative disorders</span><span class="headingEndMark"> — </span>Myeloproliferative disorders (eg, myelofibrosis, polycythemia vera, and leukemia) with extramedullary hematopoiesis may cause a hypermetabolic state with increased oxygen consumption and decreased systemic vascular resistance [<a href="#rid1">1</a>]. Some patients with myelofibrosis have isolated right HF, which may be caused by the effects of circulating progenitor cells on right ventricular and pulmonary vascular function.</p><p class="headingAnchor" id="H3440162577"><span class="h4">Hyperthyroidism</span><span class="headingEndMark"> — </span>Hyperthyroidism causes high-output HF by a combination of metabolic, vascular, and direct myocardial effects. Thyroid hormone is a potent regulator of whole body metabolism; an increased circulating level of thyroxine produces an increase in metabolism accompanied by a reduction in systemic vascular resistance and an obligatory increase in cardiac output [<a href="#rid69">69-72</a>]. Hyperthyroidism may create a hyperdynamic circulatory state via enhanced sympathoadrenal activation [<a href="#rid70">70,73</a>] as well as by direct action of thyroid hormone, which possesses strong, positive chronotropic and inotropic effects [<a href="#rid74">74,75</a>]. The heart rate is increased and pulse pressure is widened. The metabolic and circulatory changes in hyperthyroid individuals are similar to those in normal volunteers during <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> infusion [<a href="#rid70">70</a>]. Administration of sympatholytic agents such as beta blockers to patients with hyperthyroidism can decrease the heart rate, cardiac output, and pulse pressure toward normal [<a href="#rid70">70</a>]. However, sympatholytic agents alone do not completely normalize cardiac parameters in these patients. (See  <a class="medical medical_review" href="/d/html/7853.html" rel="external">"Cardiovascular effects of hyperthyroidism"</a>.)</p><p>Among patients with hyperthyroidism and HF, left ventricular ejection fraction (LVEF) may be preserved or reduced. LV systolic dysfunction may be due to tachycardia-mediated cardiomyopathy (eg, atrial fibrillation with a rapid ventricular response) or concomitant cardiac disease [<a href="#rid76">76,77</a>]. Chronic volume overload, hypercontractility, and tachycardia contribute to the development of cardiac hypertrophy in patients with hyperthyroidism [<a href="#rid70">70,76,78</a>]. It has been postulated that hyperthyroidism may have a cardiotoxic effect, perhaps mediated by beta-adrenergic stimulation [<a href="#rid76">76</a>]. Direct activation of protein-synthesizing processes by thyroid hormone may also contribute to myocardial hypertrophy. Patients with hyperthyroidism have an abnormally low or absent increase in LVEF in response to exercise [<a href="#rid79">79-81</a>]. Hyperthyroidism can also cause a hyperdynamic right ventricle that normalizes following treatment to restore a euthyroid state [<a href="#rid82">82</a>]. Reversible right ventricular failure and pulmonary hypertension has also been reported [<a href="#rid83">83</a>]. (See  <a class="medical medical_review" href="/d/html/1004.html" rel="external">"Epidemiology, risk factors, and prevention of atrial fibrillation"</a> and  <a class="medical medical_review" href="/d/html/7853.html" rel="external">"Cardiovascular effects of hyperthyroidism", section on 'Heart failure'</a> and  <a class="medical medical_review" href="/d/html/1062.html" rel="external">"Arrhythmia-induced cardiomyopathy"</a>.)</p><p class="headingAnchor" id="H4011768379"><span class="h3">Myocardial and peripheral vascular effects</span><span class="headingEndMark"> — </span>The following conditions are postulated as having peripheral vascular effects as well as possible direct myocardial effects that may lead to high-output HF.</p><p class="headingAnchor" id="H614488342"><span class="h4">Sepsis</span><span class="headingEndMark"> — </span>Sepsis, a clinical syndrome caused by a dysregulated inflammatory response to infection, is associated with a spectrum of hemodynamic alterations: there is frequently initial hypovolemia (prior to fluid resuscitation) with varying alterations in systemic vascular resistance and cardiac output [<a href="#rid84">84,85</a>]. Low systemic vascular resistance is frequently accompanied by high cardiac output, but patients with sepsis with HF often have reversible systolic and/or diastolic LV and/or right ventricular dysfunction, which limits cardiac reserve [<a href="#rid84">84,85</a>].</p><p>Infection leads to an inflammatory response, releasing tumor necrosis factor-alpha, interleukin-1-beta, Il-6, and other proinflammatory cytokines. These lead to systemic vasodilation and may decrease cardiac contractility via inducible nitric oxide synthase [<a href="#rid86">86,87</a>].</p><p class="headingAnchor" id="H3981865476"><span class="h4">Beriberi</span><span class="headingEndMark"> — </span>Beriberi heart disease is due to severe thiamine (vitamin B1) deficiency. The mechanism for high-output failure in beriberi may be multifactorial, with high cardiac output superimposed on myocardial dysfunction. Thiamine deficiency initially presents as a high-output state secondary to vasodilation and an increase in blood volume [<a href="#rid88">88</a>]; this is followed by eventual depression of myocardial function and the development of a low-output state [<a href="#rid89">89</a>]. The high cardiac output is due to reduced systemic vascular resistance and augmented venous return. It is not clear what causes the marked reduction in systemic vascular resistance, but it may reflect direct vasomotor depression [<a href="#rid88">88</a>].</p><p>Postmortem gross examination of the heart shows dilation without other changes. Histopathologic study shows nonspecific changes, including myocardial vacuolization and interstitial myocardial edema in the early stages, with myocyte hypertrophy, fibrosis, and cellular infiltration in the chronic phase [<a href="#rid90">90</a>]. Cardiac magnetic resonance imaging may be used to demonstrate myocardial edema in severe thiamine deficiency [<a href="#rid91">91</a>].</p><p>A biochemical lesion due to thiamine deficiency may contribute to high output and myocardial dysfunction in beriberi [<a href="#rid92">92,93</a>]. Pyruvate and lactate are important substrates for oxidation and energy production in heart muscle, but thiamine deficiency blocks their utilization. Specifically, thiamine pyrophosphate is needed for the decarboxylation of pyruvate and its subsequent oxidation in the citric acid cycle. As a result of thiamine deficiency, pyruvate and its precursor lactate build up in the blood; increased blood lactate level has been used in the diagnosis of beriberi but is nonspecific [<a href="#rid94">94</a>]. Thiamine deficiency also inhibits the function of the hexose monophosphate shunt, contributing to insufficient oxygenation of the tissues. (See  <a class="medical medical_review" href="/d/html/5367.html" rel="external">"Overview of water-soluble vitamins"</a>.)</p><p class="headingAnchor" id="H449980023"><span class="h4">Acromegaly</span><span class="headingEndMark"> — </span>Growth hormone is important for the maintenance of normal cardiac function [<a href="#rid95">95</a>]. HF is not uncommon in newly diagnosed acromegaly [<a href="#rid96">96</a>] (see  <a class="medical medical_review" href="/d/html/6633.html" rel="external">"Causes and clinical manifestations of acromegaly"</a>). In a review of 102 such patients, 10 had overt HF at the time of diagnosis [<a href="#rid97">97</a>]. Compared with those without HF, these patients had an increase in LV mass index that was largely due to chamber dilation, a reduction in LVEF (42 versus 66 percent), and a significant elevation in cardiac index (4.3 versus 3.5 L/min per m<sup>2</sup> versus 3.1 L/min per m<sup>2</sup> in controls). A contemporary, multinational registry of over 3000 patients reported low rates of cardiovascular complications (&lt;5 percent) in adults with newly diagnosed acromegaly [<a href="#rid98">98</a>]. (See  <a class="medical medical_review" href="/d/html/6633.html" rel="external">"Causes and clinical manifestations of acromegaly"</a>.)</p><p class="headingAnchor" id="H354774281"><span class="h4">Mitochondrial diseases</span><span class="headingEndMark"> — </span>Mitochondrial diseases are a cause of high-output failure associated with lactic acidosis, reduced systemic vascular resistance caused by disturbed oxidative metabolism, and cardiomyopathy [<a href="#rid99">99,100</a>]. (See  <a class="medical medical_review" href="/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H1717319682"><span class="h4">Anagrelide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8593" href="/d/drug information/8593.html" rel="external">Anagrelide</a>, a phosphodiesterase III inhibitor used in the treatment of essential thrombocythemia [<a href="#rid101">101</a>], has been identified as a cause of high-output HF. Anagrelide may cause vasodilation and may also have positive inotropic and chronotropic effects. Case reports of cardiomyopathy secondary to anagrelide have also been reported [<a href="#rid102">102</a>].</p><p class="headingAnchor" id="H2379658233"><span class="h3">Other</span></p><p class="headingAnchor" id="H4029501855"><span class="h4">Anemia</span><span class="headingEndMark"> — </span>Anemia has been identified as a cause of high-output HF (eg, in patients with beta-thalassemia intermedia [<a href="#rid103">103,104</a>]), but the mechanism of HF in anemia is not completely understood. Anemia, even when severe, rarely causes HF, and when it does, it is likely that the high-output failure is superimposed upon some cardiac abnormality such as valvular heart disease or underlying LV dysfunction [<a href="#rid105">105</a>]. In a seminal study involving right heart catheterization, normal cardiac hemodynamics were maintained in patients with hemoglobin values as low as 7 g/dL [<a href="#rid106">106</a>]. When the hemoglobin was 5 to 7 g/dL, cardiac output increased and HF did not occur. HF developed in the absence of underlying heart disease only with severe anemia (ie, hemoglobin less than 5 g/dL).</p><p>Decreased LV afterload secondary to reduced serum viscosity may play a role [<a href="#rid107">107</a>]. Anemia may also cause peripheral vasodilation [<a href="#rid108">108</a>] due to endothelial dysfunction [<a href="#rid109">109</a>]. The loss of hemoglobin is partly compensated for by an increase in cardiac output and widening of the arteriovenous O<sub>2</sub> difference. Thus, severe anemia can result in LV volume overload and increased stroke volume that can alter LV function [<a href="#rid107">107</a>]. As an example, one study of serial echocardiograms in 124 patients with sickle cell anemia found progressive chamber enlargement and increased LV mass [<a href="#rid110">110</a>]. Moreover, the LV systolic time interval and the LV pre-ejection period were progressively higher in the sickle cell group compared with same-aged controls, suggesting a decline in LV function with time.</p><p>Chronic anemia may also contribute to the development of HF from other causes. In patients with HF due to other causes, there is evidence that chronic anemia is associated with the progression of HF, but anemia is also associated with a number of common comorbidities. There is conflicting evidence regarding whether anemia is an independent cause of HF progression and worse outcomes, or if it is simply associated with overall disease severity. (See  <a class="medical medical_review" href="/d/html/3483.html" rel="external">"Evaluation and management of anemia and iron deficiency in adults with heart failure"</a>.)</p><p class="headingAnchor" id="H2632037089"><span class="h4">Chronic pulmonary disease</span><span class="headingEndMark"> — </span>Chronic pulmonary disease with associated hypoxia and hypercapnia is associated with high-output HF, which may be caused by reduced systemic vascular resistance, salt and water retention, and impaired renal blood flow [<a href="#rid1">1</a>]. Some patients with high-output HF associated with lung disease present with isolated right HF, which may be secondary to hypoxic pulmonary vasoconstriction with systemic arterial vasodilation [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Additional precipitants of high output</span><span class="headingEndMark"> — </span>There are a number of physiologic conditions that can substantially increase cardiac output and contribute to a high-output state that may precipitate HF:</p><p class="bulletIndent1"><span class="glyph">●</span>Physical or emotional stress – Stress may provoke a state of catecholamine excess with increased cardiac output and variable effects on systemic vascular resistance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exercise – With exercise, cardiac output increases, and systemic vascular resistance generally decreases. (See  <a class="medical medical_review" href="/d/html/1433.html" rel="external">"Exercise physiology"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fever – Fever increases metabolic demand and produces vasodilation, especially in the skin. Resolution of the fever is accompanied by a reduction in cardiac output to normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hot climate – A hot, and especially humid, environment increases cardiac output through mechanisms similar to fever [<a href="#rid111">111</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy is associated with increased metabolic demand, increased blood volume, placental blood flow (which may act as an arteriovenous shunt), reduced systemic vascular resistance, elevated maternal heart rate (by 15 to 20 beats per minute), and increased resting cardiac output (by 30 to 50 percent above baseline). (See  <a class="medical medical_review" href="/d/html/443.html" rel="external">"Maternal adaptations to pregnancy: Cardiovascular and hemodynamic changes"</a>.)</p><p></p><p class="bulletIndent1">These hemodynamic changes may precipitate HF in pregnant women with an underlying cardiac disorder or who develop peripartum cardiomyopathy [<a href="#rid112">112</a>]. Women with an underlying cause for a high cardiac output, such as an arteriovenous fistula, hereditary telangiectasia, or anemia, are more likely to develop high-output HF during pregnancy [<a href="#rid113">113-116</a>]. In addition, multiple pregnancies in a patient with underlying fistulas may progressively exacerbate vascular malformations and lead to the development of HF despite a history of previous uncomplicated pregnancies. (See  <a class="medical medical_review" href="/d/html/3507.html" rel="external">"Management of heart failure during pregnancy"</a>.)</p><p></p><p class="headingAnchor" id="H3445715294"><span class="h2">Role of concurrent cardiac conditions</span><span class="headingEndMark"> — </span>Causes contributing to high cardiac output are rarely the sole cause of HF; in most patients with high-output HF, HF is provoked by high output in the setting of reduced ventricular reserve (systolic and/or diastolic dysfunction) from some underlying cardiac problem. Examples include patients with:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe functional tricuspid regurgitation</strong> – In a study of 132 patients undergoing transcatheter tricuspid valve repair, patients with high cardiac index (&gt;2.6 L/min/m<sup>2</sup>) were characterized by larger inferior vena cava diameters, reduced liver function, higher incidence of ascites, and markedly reduced systemic vascular resistance [<a href="#rid117">117</a>]. Postprocedure, these patients were more likely to have persistent signs of right ventricular dysfunction (ie, elevated right atrial pressures and right ventricular enlargement) and a higher risk of mortality (42 versus 20 percent in the group with intermediate cardiac output; adjusted hazard ratio 4.7, 95% CI 1.8-13.0).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Failing Fontan circulation</strong> – In a study of 139 adults with a Fontan circulation (extracardiac conduit or lateral tunnel), the subgroup of patients (n = 11) with portosystemic venous shunts had increased cardiac index (5.3 L/min/m<sup>2</sup>) and decreased systemic vascular resistance (7.1 Wood units) [<a href="#rid118">118</a>].</p><p></p><p class="bulletIndent1">In another small series of failing Fontan patients with high cardiac output, vasoconstrictor therapy with intravenous <a class="drug drug_general" data-topicid="9709" href="/d/drug information/9709.html" rel="external">norepinephrine</a> and/or oral <a class="drug drug_general" data-topicid="9651" href="/d/drug information/9651.html" rel="external">midodrine</a> increased systolic blood pressure, arterial oxygen saturation, and systemic vascular resistance and decreased hospital readmissions [<a href="#rid119">119</a>].</p><p></p><p>Thus, the presence of high-output HF should prompt a search for another underlying cardiovascular condition, including a search for acquired arteriovenous fistulas.</p><p>In some clinical settings, multiple factors may contribute to the development of HF. As an example, in patients with end-stage kidney disease who have high-output HF related to hemodialysis, arteriovenous access, anemia (which is now less common due to the widespread use of erythropoietin), and volume expansion (due to salt and water retention) caused by kidney disease may contribute to the high-output state. As an example:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 140 patients receiving outpatient dialysis therapy, arteriovenous fistula flow was positively associated with an upper arm fistula, body mass index, and N-terminal pro-B-type natriuretic peptide level and negatively associated with diabetes [<a href="#rid120">120</a>]. Notably, high arteriovenous fistula flow was not associated with extracellular volume in this cohort.</p><p></p><p>Premature atherosclerosis and LV hypertrophy due to hypertension are common in patients with end-stage kidney disease. Thus, patients with end-stage kidney disease frequently have heart disease with increased susceptibility to HF in the setting of an elevated cardiac output. Another example of multiple factors causing HF is high-output HF caused by the combination of morbid obesity plus cirrhosis due to nonalcoholic fatty liver disease. (See  <a class="medical medical_review" href="/d/html/1958.html" rel="external">"Evaluation and management of heart failure caused by hemodialysis arteriovenous access"</a> and  <a class="medical medical_review" href="/d/html/1846.html" rel="external">"Overview of screening and diagnosis of heart disease in patients on dialysis"</a>.)</p><p class="headingAnchor" id="H1902404907"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115372.html" rel="external">"Society guideline links: Heart failure in adults"</a>.)</p><p class="headingAnchor" id="H571943297"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>High-output heart failure (HF) is an uncommon type of HF. The prevalence of this disorder is uncertain, particularly since the potential contributory role of high-output syndromes to HF may not be appreciated in many cases. Although high-output states are uncommon as a sole cause of HF, they may more frequently contribute to HF in patients with underlying cardiovascular disease and reduced myocardial reserve. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High-output HF is characterized by elevated cardiac output, low systemic vascular resistance (due to peripheral vasodilation or arteriovenous shunting), and low arterial-venous oxygen content difference; some types are associated with increased oxygen consumption (reflecting increased metabolic demand). In the setting of high-output HF, the elevation in cardiac output is greater than that required to meet metabolic demand. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are a variety of pathophysiologic processes that result in a high-output state. Some causes appear to have primarily peripheral vascular effects, while other causes may have metabolic effects or myocardial as well as peripheral vascular effects. The distinction between these categories is imperfect since some causes are associated with combinations of peripheral vascular, metabolic, and myocardial effects (eg, hyperthyroidism, beriberi). Peripheral vascular effects can have secondary effects on cardiac structure and function. (See <a class="local">'Causes and their mechanisms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Morbid obesity, arteriovenous fistula, cirrhosis, erythroderma, and carcinoid syndrome are among the causes of high-output HF with peripheral vascular effects. (See <a class="local">'Peripheral vascular effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Myeloproliferative disorders and hyperthyroidism are causes of high-output HF associated with increased metabolic demand.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sepsis, beriberi, acromegaly, and mitochondrial diseases are causes of high-output HF with myocardial and peripheral vascular effects.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other causes of high-output HF include anemia and chronic pulmonary disease.</p><p></p><p class="headingAnchor" id="H1844506696"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Amir Haghighat, MD, FACC, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Reddy YN, Melenovsky V, Redfield MM, et al. High-Output Heart Failure: A 15-Year Experience. J Am Coll Cardiol 2016; 68:473.</a></li><li><a class="nounderline abstract_t">Uddin MM, Mir T, Briasoulis A, et al. Clinical outcomes and 30-day readmissions associated with high-output heart failure. Hellenic J Cardiol 2023; 69:24.</a></li><li><a class="nounderline abstract_t">Honetschlägerová Z, Hejnová L, Novotný J, et al. Effects of Renal Denervation on the Enhanced Renal Vascular Responsiveness to Angiotensin II in High-Output Heart Failure: Angiotensin II Receptor Binding Assessment and Functional Studies in Ren-2 Transgenic Hypertensive Rats. Biomedicines 2021; 9.</a></li><li><a class="nounderline abstract_t">Díaz HS, Andrade DC, Toledo C, et al. Inhibition of Brainstem Endoplasmic Reticulum Stress Rescues Cardiorespiratory Dysfunction in High Output Heart Failure. Hypertension 2021; 77:718.</a></li><li><a class="nounderline abstract_t">Anand IS. High-output heart failure revisted. J Am Coll Cardiol 2016; 68:483.</a></li><li><a class="nounderline abstract_t">de Ávila DX, Villacorta H, de Andrade Martins W, Mesquita ET. High-output Cardiac Failure: A Forgotten Phenotype in Clinical Practice. Curr Cardiol Rev 2022; 18:e050821195319.</a></li><li><a class="nounderline abstract_t">Anand IS, Florea VG. High Output Cardiac Failure. Curr Treat Options Cardiovasc Med 2001; 3:151.</a></li><li><a class="nounderline abstract_t">Holzem KM, Marmerstein JT, Madden EJ, Efimov IR. Diet-induced obesity promotes altered remodeling and exacerbated cardiac hypertrophy following pressure overload. Physiol Rep 2015; 3.</a></li><li><a class="nounderline abstract_t">Packer M. Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity. Circulation 2018; 137:1614.</a></li><li><a class="nounderline abstract_t">Borlaug BA, Jensen MD, Kitzman DW, et al. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118:3434.</a></li><li><a class="nounderline abstract_t">Rozenbaum Z, Topilsky Y, Khoury S, et al. Association of body mass index and diastolic function in metabolically healthy obese with preserved ejection fraction. Int J Cardiol 2019; 277:147.</a></li><li><a class="nounderline abstract_t">Styczynski G, Kalinowski P, Michałowski Ł, et al. Cardiac Morphology, Function, and Hemodynamics in Patients With Morbid Obesity and Nonalcoholic Steatohepatitis. J Am Heart Assoc 2021; 10:e017371.</a></li><li><a class="nounderline abstract_t">Tobe A, Tanaka A, Yoshida S, et al. High-output Heart Failure Caused by a Tumor-related Arteriovenous Fistula: A Case Report and Literature Review. Intern Med 2021; 60:2979.</a></li><li><a class="nounderline abstract_t">Alcázar R, de la Torre M, Peces R. Symptomatic intrarenal arteriovenous fistula detected 25 years after percutaneous renal biopsy. Nephrol Dial Transplant 1996; 11:1346.</a></li><li><a class="nounderline abstract_t">Lekuona I, Laraudogoitia E, Salcedo A, Sádaba M. Congestive heart failure in a hypertensive patient (don't forget the stethoscope). Lancet 2001; 357:358.</a></li><li><a class="nounderline abstract_t">Rabtsun A, Lejay A, Saaya S, et al. Post-Traumatic Arteriovenous Fistulas Leading to Heart Failure. EJVES Vasc Forum 2021; 53:14.</a></li><li><a class="nounderline abstract_t">Wenzl FA, Miljkovic SS, Dabestani PJ, et al. A systematic review and individual patient data meta-analysis of heart failure as a rare complication of traumatic arteriovenous fistulas. J Vasc Surg 2021; 73:1087.</a></li><li><a class="nounderline abstract_t">Sigler L, Gutiérrez-Carreño R, Martínez-López C, et al. Aortocava fistula: experience with five patients. Vasc Surg 2001; 35:207.</a></li><li><a class="nounderline abstract_t">Lebon A, Agueznai M, Labombarda F. High-output heart failure resulting from chronic aortocaval fistula. Circulation 2013; 127:527.</a></li><li><a class="nounderline abstract_t">Wasse H, Singapuri MS. High-output heart failure: how to define it, when to treat it, and how to treat it. Semin Nephrol 2012; 32:551.</a></li><li><a class="nounderline abstract_t">Malik J, Kudlicka J, Tesar V, Linhart A. Cardiac safety in vascular access surgery and maintenance. Contrib Nephrol 2015; 184:75.</a></li><li><a class="nounderline abstract_t">Samarendra P, Ramkumar M, Sharma V, Kumari S. Cardiorenal syndrome in renal transplant recipients - It's the fistula at fault: A case series. Clin Transplant 2018; 32:e13417.</a></li><li><a class="nounderline abstract_t">Warner ED, Brailovsky Y, Oliveros E, et al. High-Output Heart Failure, Pulmonary Hypertension and Right Ventricular Failure in Patients With Arteriovenous Fistulas: A Call to Action. J Card Fail 2023; 29:979.</a></li><li><a class="nounderline abstract_t">Fraser CD 3rd, Grimm JC, Liu RH, et al. Removal of Noninfected Arteriovenous Fistulae after Kidney Transplantation is a Safe and Beneficial Management Strategy for Unused Dialysis Access. Ann Vasc Surg 2018; 53:128.</a></li><li><a class="nounderline abstract_t">Dubin AH, Martin-Velez J, Shenkute NT, Toledo AH. Long-Term Safety, Efficacy, Indications, and Criteria of Arteriovenous Fistula Ligation Following Kidney Transplant: A Patient-Driven Approach. Exp Clin Transplant 2023; 21:487.</a></li><li><a class="nounderline abstract_t">Huang XM, Yu F, Wang Y, et al. Effect of proximal artery restriction on flow reduction and cardiac function in hemodialysis patients with high-flow arteriovenous fistulas. J Vasc Surg 2023; 78:526.</a></li><li><a class="nounderline abstract_t">Dahl JS, Andersen C, Duvnjak S, Moller JE. Two cases of high-output heart failure as initial presentation of iliac arteriovenous fistula. BMJ Case Rep 2018; 2018.</a></li><li><a class="nounderline abstract_t">Braverman AC, Steiner MA, Picus D, White H. High-output congestive heart failure following transjugular intrahepatic portal-systemic shunting. Chest 1995; 107:1467.</a></li><li><a class="nounderline abstract_t">Colombato LA, Spahr L, Martinet JP, et al. Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients. Gut 1996; 39:600.</a></li><li><a class="nounderline abstract_t">Ohlow MA, Secknus MA, von Korn H, et al. Incidence and outcome of femoral vascular complications among 18,165 patients undergoing cardiac catheterisation. Int J Cardiol 2009; 135:66.</a></li><li><a class="nounderline abstract_t">Kelm M, Perings SM, Jax T, et al. Incidence and clinical outcome of iatrogenic femoral arteriovenous fistulas: implications for risk stratification and treatment. J Am Coll Cardiol 2002; 40:291.</a></li><li><a class="nounderline abstract_t">Geng W, Fu X, Gu X, et al. Safety and feasibility of transulnar versus transradial artery approach for coronary catheterization in non-selective patients. Chin Med J (Engl) 2014; 127:1222.</a></li><li><a class="nounderline abstract_t">Hahalis G, Tsigkas G, Kakkos S, et al. Vascular Complications Following Transradial and Transulnar Coronary Angiography in 1600 Consecutive Patients. Angiology 2016; 67:438.</a></li><li><a class="nounderline abstract_t">Zilinyi RS, Sethi SS, Parikh MA, Parikh SA. Iatrogenic Arteriovenous Fistula Following Femoral Access Precipitating High-Output Heart Failure. JACC Case Rep 2021; 3:421.</a></li><li><a class="nounderline abstract_t">Wermers RA, Tiegs RD, Atkinson EJ, et al. Morbidity and mortality associated with Paget's disease of bone: a population-based study. J Bone Miner Res 2008; 23:819.</a></li><li><a class="nounderline abstract_t">Kohrt H, Logan A, Temmins C, et al. Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma. Leuk Lymphoma 2008; 49:581.</a></li><li><a class="nounderline abstract_t">McBride W, Jackman JD Jr, Grayburn PA. Prevalence and clinical characteristics of a high cardiac output state in patients with multiple myeloma. Am J Med 1990; 89:21.</a></li><li><a class="nounderline abstract_t">Inanir S, Haznedar R, Atavci S, Unlü M. Arteriovenous shunting in patients with multiple myeloma and high-output failure. J Nucl Med 1998; 39:1.</a></li><li><a class="nounderline abstract_t">Morales-Piga AA, Moya JL, Bachiller FJ, et al. Assessment of cardiac function by echocardiography in Paget's disease of bone. Clin Exp Rheumatol 2000; 18:31.</a></li><li><a class="nounderline abstract_t">Sanyal SK, Saldivar V, Coburn TP, et al. Hyperdynamic heart failure due to A-V fistula associated with Wilms' tumor. Pediatrics 1976; 57:564.</a></li><li><a class="nounderline abstract_t">Hayek S, Kung R, Barb I, et al. Digging deep: high output heart failure in renal cell carcinoma. Am J Med 2014; 127:22.</a></li><li><a class="nounderline abstract_t">Ersbøll M, Plamboeck A, Gustafsson F, Mosholt KSS. Case of High Output Heart Failure Caused by Renal Clear Cell Carcinoma. Circ Heart Fail 2023; 16:e010656.</a></li><li><a class="nounderline abstract_t">Ranjbar M, Amin A, Amin A, et al. High cardiac output state due to pelvic arterio-venous shunt: a case report and review of the literature. ESC Heart Fail 2023; 10:2702.</a></li><li><a class="nounderline abstract_t">Lim FY, Coleman A, Polzin W, et al. Giant chorioangiomas: perinatal outcomes and techniques in fetoscopic devascularization. Fetal Diagn Ther 2015; 37:18.</a></li><li><a class="nounderline abstract_t">Szilagyi DE, Smith RF, Elliott JP, Hageman JH. Congenital arteriovenous anomalies of the limbs. Arch Surg 1976; 111:423.</a></li><li><a class="nounderline abstract_t">Dotan M, Lorber A. Congestive heart failure with diffuse neonatal hemangiomatosis--case report and literature review. Acta Paediatr 2013; 102:e232.</a></li><li><a class="nounderline abstract_t">Shah SS, Snelling BM, Sur S, et al. Scalp congenital hemangioma with associated high-output cardiac failure in a premature infant: Case report and review of literature. Interv Neuroradiol 2017; 23:102.</a></li><li><a class="nounderline abstract_t">Gossage JR, Kanj G. Pulmonary arteriovenous malformations. A state of the art review. Am J Respir Crit Care Med 1998; 158:643.</a></li><li><a class="nounderline abstract_t">Pick A, Deschamps C, Stanson AW. Pulmonary arteriovenous fistula: presentation, diagnosis, and treatment. World J Surg 1999; 23:1118.</a></li><li><a class="nounderline abstract_t">Danchin N, Thisse JY, Neimann JL, Faivre G. Osler-Weber-Rendu disease with multiple intrahepatic arteriovenous fistulas. Am Heart J 1983; 105:856.</a></li><li><a class="nounderline abstract_t">Ginon I, Decullier E, Finet G, et al. Hereditary hemorrhagic telangiectasia, liver vascular malformations and cardiac consequences. Eur J Intern Med 2013; 24:e35.</a></li><li><a class="nounderline abstract_t">Shovlin CL, Awan I, Cahilog Z, et al. Reported cardiac phenotypes in hereditary hemorrhagic telangiectasia emphasize burdens from arrhythmias, anemia and its treatments, but suggest reduced rates of myocardial infarction. Int J Cardiol 2016; 215:179.</a></li><li><a class="nounderline abstract_t">Kritharis A, Al-Samkari H, Kuter DJ. Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective. Haematologica 2018; 103:1433.</a></li><li><a class="nounderline abstract_t">Solela G, Adamseged M, Mohammed A. Hereditary hemorrhagic telangiectasia in a 42-year-old Ethiopian man presenting with severe anemia and high-output heart failure: A case report with literature review. Clin Case Rep 2023; 11:e7694.</a></li><li><a class="nounderline abstract_t">Yamamoto H, Itamoto C, Yamaguchi T, Koshyo T. Severe Hypoxemia Caused by High-Output Heart Failure and Pulmonary Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia. JACC Case Rep 2021; 3:1863.</a></li><li><a class="nounderline abstract_t">Vaksmann G, Rey C, Marache P, et al. Severe congestive heart failure in newborns due to giant cutaneous hemangiomas. Am J Cardiol 1987; 60:392.</a></li><li><a class="nounderline abstract_t">Weitz NA, Lauren CT, Starc TJ, et al. Congenital cutaneous hemangioma causing cardiac failure: a case report and review of the literature. Pediatr Dermatol 2013; 30:e180.</a></li><li><a class="nounderline abstract_t">Hosono S, Ohno T, Kimoto H, et al. Successful transcutaneous arterial embolization of a giant hemangioma associated with high-output cardiac failure and Kasabach-Merritt syndrome in a neonate: a case report. J Perinat Med 1999; 27:399.</a></li><li><a class="nounderline abstract_t">Khanna D, Chakravarty P, Arora P, et al. Large multifocal cutaneous hemangioma along lines of Blaschko with cardiac failure treated with propranolol. Pediatr Dermatol 2015; 32:e18.</a></li><li><a class="nounderline abstract_t">Shin WJ, Song JG, Jun IG, et al. Effect of ventriculo-arterial coupling on transplant outcomes in cirrhotics: Analysis of pressure-volume curve relations. J Hepatol 2017; 66:328.</a></li><li><a class="nounderline abstract_t">Bernal V, Pascual I, Esquivias P, et al. Cardiac hemodynamic profiles and pro-B-type natriuretic Peptide in cirrhotic patients undergoing liver transplantation. Transplant Proc 2009; 41:985.</a></li><li><a class="nounderline abstract_t">Cichoz-Lach H, Celiński K, Słomka M, Kasztelan-Szczerbińska B. Pathophysiology of portal hypertension. J Physiol Pharmacol 2008; 59 Suppl 2:231.</a></li><li><a class="nounderline abstract_t">Milani A, Zaccaria R, Bombardieri G, et al. Cirrhotic cardiomyopathy. Dig Liver Dis 2007; 39:507.</a></li><li><a class="nounderline abstract_t">Schrier RW. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am J Med 2006; 119:S47.</a></li><li><a class="nounderline abstract_t">Pacca R, Maddukuri P, Pandian NG, Kuvin JT. Echocardiographic detection of intrapulmonary shunting in a patient with hepatopulmonary syndrome: case report and review of the literature. Echocardiography 2006; 23:56.</a></li><li><a class="nounderline abstract_t">Páll A, Czifra A, Vitális Z, et al. Pathophysiological and clinical approach to cirrhotic cardiomyopathy. J Gastrointestin Liver Dis 2014; 23:301.</a></li><li><a class="nounderline abstract_t">Yun D, Heywood JT. Metastatic carcinoid disease presenting solely as high-output heart failure. Ann Intern Med 1994; 120:45.</a></li><li><a class="nounderline abstract_t">Meijer WC, van Veldhuisen DJ, Kema IP, et al. Cardiovascular abnormalities in patients with a carcinoid syndrome. Neth J Med 2002; 60:10.</a></li><li><a class="nounderline abstract_t">Wilson BE, Newmark SR. Thyrotoxicosis-induced congestive heart failure in an urban hospital. Am J Med Sci 1994; 308:344.</a></li><li><a class="nounderline abstract_t">Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344:501.</a></li><li><a class="nounderline abstract_t">Lewis BS, Ehrenfeld EN, Lewis N, Gotsman MS. Echocardiographic LV function in thyrotoxicosis. Am Heart J 1979; 97:460.</a></li><li><a class="nounderline abstract_t">Riaz K, Forker AD, Isley WL, et al. Hyperthyroidism: a "curable" cause of congestive heart failure--three case reports and a review of the literature. Congest Heart Fail 2003; 9:40.</a></li><li><a class="nounderline abstract_t">BREWSTER WR Jr, ISAACS JP, OSGOOD PF, KING TL. The hemodynamic and metabolic interrelationships in the activity of epinephrine, norepinephrine and the thyroid hormones. Circulation 1956; 13:1.</a></li><li><a class="nounderline abstract_t">Johnson PN, Freedberg AS, Marshall JM. Action of thyroid hormone on the transmembrane potentials from sinoatrial node cells and atrial muscle cells in isolated atria of rabbits. Cardiology 1973; 58:273.</a></li><li><a class="nounderline abstract_t">Goodkind MJ, Dambach GE, Thyrum PT, Luchi RJ. Effect of thyroxine on ventricular myocardial contractility and ATPase activity in guinea pigs. Am J Physiol 1974; 226:66.</a></li><li><a class="nounderline abstract_t">Siu CW, Yeung CY, Lau CP, et al. Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart 2007; 93:483.</a></li><li><a class="nounderline abstract_t">Biondi B. Mechanisms in endocrinology: Heart failure and thyroid dysfunction. Eur J Endocrinol 2012; 167:609.</a></li><li><a class="nounderline abstract_t">Di Bello V, Aghini-Lombardi F, Monzani F, et al. Early abnormalities of left ventricular myocardial characteristics associated with subclinical hyperthyroidism. J Endocrinol Invest 2007; 30:564.</a></li><li><a class="nounderline abstract_t">Forfar JC, Muir AL, Sawers SA, Toft AD. Abnormal left ventricular function in hyperthyroidism: evidence for a possible reversible cardiomyopathy. N Engl J Med 1982; 307:1165.</a></li><li><a class="nounderline abstract_t">Iskandrian AS, Rose L, Hakki AH, et al. Cardiac performance in thyrotoxicosis: analysis of 10 untreated patients. Am J Cardiol 1983; 51:349.</a></li><li><a class="nounderline abstract_t">Kahaly GJ, Kampmann C, Mohr-Kahaly S. Cardiovascular hemodynamics and exercise tolerance in thyroid disease. Thyroid 2002; 12:473.</a></li><li><a class="nounderline abstract_t">Teasdale SL, Inder WJ, Stowasser M, Stanton T. Hyperdynamic Right Heart Function in Graves' Hyperthyroidism Measured by Echocardiography Normalises on Restoration of Euthyroidism. Heart Lung Circ 2017; 26:580.</a></li><li><a class="nounderline abstract_t">Faccia M, Porfidia A, Montalto M. Acute Right Ventricular Heart Failure: An Uncommon Case of Thyrotoxicosis. Am J Med Sci 2018; 356:309.</a></li><li><a class="nounderline abstract_t">Vieillard-Baron A, Cecconi M. Understanding cardiac failure in sepsis. Intensive Care Med 2014; 40:1560.</a></li><li><a class="nounderline abstract_t">Zaky A, Deem S, Bendjelid K, Treggiari MM. Characterization of cardiac dysfunction in sepsis: an ongoing challenge. Shock 2014; 41:12.</a></li><li><a class="nounderline abstract_t">Merx MW, Weber C. Sepsis and the heart. Circulation 2007; 116:793.</a></li><li><a class="nounderline abstract_t">Vielma AZ, León L, Fernández IC, et al. Nitric Oxide Synthase 1 Modulates Basal and β-Adrenergic-Stimulated Contractility by Rapid and Reversible Redox-Dependent S-Nitrosylation of the Heart. PLoS One 2016; 11:e0160813.</a></li><li><a class="nounderline abstract_t">Akbarian M, Yankopoulos NA, Abelmann WH. Hemodynamic studies in beriberi heart disease. Am J Med 1966; 41:197.</a></li><li><a class="nounderline abstract_t">Abelmann WH, Lorell BH. The challenge of cardiomyopathy. J Am Coll Cardiol 1989; 13:1219.</a></li><li><a class="nounderline abstract_t">Ikram H, Maslowski AH, Smith BL, Nicholls MG. The haemodynamic, histopathological and hormonal features of alcoholic cardiac beriberi. Q J Med 1981; 50:359.</a></li><li><a class="nounderline abstract_t">Essa E, Velez MR, Smith S, et al. Cardiovascular magnetic resonance in wet beriberi. J Cardiovasc Magn Reson 2011; 13:41.</a></li><li><a class="nounderline abstract_t">Ahmed M, Azizi-Namini P, Yan AT, Keith M. Thiamin deficiency and heart failure: the current knowledge and gaps in literature. Heart Fail Rev 2015; 20:1.</a></li><li><a class="nounderline abstract_t">Lei Y, Zheng MH, Huang W, et al. Wet beriberi with multiple organ failure remarkably reversed by thiamine administration: A case report and literature review. Medicine (Baltimore) 2018; 97:e0010.</a></li><li><a class="nounderline abstract_t">Hung YH, Yu AL, Chen CK, et al. Pulmonary artery catheter usage in diagnosis of Shoshin beriberi presented with unexplained lactic acidosis. ESC Heart Fail 2023; 10:2686.</a></li><li><a class="nounderline abstract_t">Isgaard J, Arcopinto M, Karason K, Cittadini A. GH and the cardiovascular system: an update on a topic at heart. Endocrine 2015; 48:25.</a></li><li><a class="nounderline abstract_t">Giustina A, Mancini T, Boscani PF, et al. Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study. J Endocrinol Invest 2008; 31:731.</a></li><li><a class="nounderline abstract_t">Damjanovic SS, Neskovic AN, Petakov MS, et al. High output heart failure in patients with newly diagnosed acromegaly. Am J Med 2002; 112:610.</a></li><li><a class="nounderline abstract_t">Petrossians P, Daly AF, Natchev E, et al. Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. Endocr Relat Cancer 2017; 24:505.</a></li><li><a class="nounderline abstract_t">Nakagawa H, Okayama S, Kamon D, et al. Refractory high output heart failure in a patient with primary mitochondrial respiratory chain disease. Intern Med 2014; 53:315.</a></li><li><a class="nounderline abstract_t">Hirose Y, Miida T, Yoshida K, et al. High-output heart failure in mitochondrial myopathy: a fulminant form with severe lactic acidosis and rhabdomyolysis. Intern Med 1993; 32:798.</a></li><li><a class="nounderline abstract_t">Engel PJ, Johnson H, Baughman RP, Richards AI. High-output heart failure associated with anagrelide therapy for essential thrombocytosis. Ann Intern Med 2005; 143:311.</a></li><li><a class="nounderline abstract_t">Singh P. A Case of Anagrelide-Induced Nonischemic Cardiomyopathy in a Patient With Essential Thrombocythemia. J Pharm Pract 2018; 31:230.</a></li><li><a class="nounderline abstract_t">Aessopos A, Kati M, Farmakis D. Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematologica 2007; 92:658.</a></li><li><a class="nounderline abstract_t">Pennell DJ, Udelson JE, Arai AE, et al. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation 2013; 128:281.</a></li><li><a class="nounderline abstract_t">Anand IS. Pathophysiology of anemia in heart failure. Heart Fail Clin 2010; 6:279.</a></li><li><a class="nounderline abstract_t">Brannon ES, Merrill AJ, Warren JV, Stead EA. THE CARDIAC OUTPUT IN PATIENTS WITH CHRONIC ANEMIA AS MEASURED BY THE TECHNIQUE OF RIGHT ATRIAL CATHETERIZATION. J Clin Invest 1945; 24:332.</a></li><li><a class="nounderline abstract_t">Metivier F, Marchais SJ, Guerin AP, et al. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant 2000; 15 Suppl 3:14.</a></li><li><a class="nounderline abstract_t">Mehta PA, Dubrey SW. High output heart failure. QJM 2009; 102:235.</a></li><li><a class="nounderline abstract_t">Teixeira RS, Terse-Ramos R, Ferreira TA, et al. Associations between endothelial dysfunction and clinical and laboratory parameters in children and adolescents with sickle cell anemia. PLoS One 2017; 12:e0184076.</a></li><li><a class="nounderline abstract_t">Balfour IC, Covitz W, Davis H, et al. Cardiac size and function in children with sickle cell anemia. Am Heart J 1984; 108:345.</a></li><li><a class="nounderline abstract_t">Nielsen B, Hales JR, Strange S, et al. Human circulatory and thermoregulatory adaptations with heat acclimation and exercise in a hot, dry environment. J Physiol 1993; 460:467.</a></li><li><a class="nounderline abstract_t">Honigberg MC, Givertz MM. Peripartum cardiomyopathy. BMJ 2019; 364:k5287.</a></li><li><a class="nounderline abstract_t">Korn TS, Thurston JM, Sherry CS, Kawalsky DL. High-output heart failure due to a renal arteriovenous fistula in a pregnant woman with suspected preeclampsia. Mayo Clin Proc 1998; 73:888.</a></li><li><a class="nounderline abstract_t">Gong B, Baken LA, Julian TM, Kubo SH. High-output heart failure due to hepatic arteriovenous fistula during pregnancy: a case report. Obstet Gynecol 1988; 72:440.</a></li><li><a class="nounderline abstract_t">Elliott JA, Rankin RN, Inwood MJ, Milne JK. An arteriovenous malformation in pregnancy: a case report and review of the literature. Am J Obstet Gynecol 1985; 152:85.</a></li><li><a class="nounderline abstract_t">Swinburne AJ, Fedullo AJ, Gangemi R, Mijangos JA. Hereditary telangiectasia and multiple pulmonary arteriovenous fistulas. Clinical deterioration during pregnancy. Chest 1986; 89:459.</a></li><li><a class="nounderline abstract_t">Unterhuber M, Kresoja KP, Besler C, et al. Cardiac output states in patients with severe functional tricuspid regurgitation: impact on treatment success and prognosis. Eur J Heart Fail 2021; 23:1784.</a></li><li><a class="nounderline abstract_t">Nagata H, Sakamoto I, Fukuoka S, et al. Portosystemic venous shunt in the patients with Fontan circulation. Heart Vessels 2021; 36:285.</a></li><li><a class="nounderline abstract_t">Miike H, Ohuchi H, Hayama Y, et al. Systemic Artery Vasoconstrictor Therapy in Fontan Patients with High Cardiac Output-Heart Failure: A Single-Center Experience. Pediatr Cardiol 2021; 42:700.</a></li><li><a class="nounderline abstract_t">Jaques DA, Davenport A. High-flow arteriovenous fistula is not associated with increased extracellular volume or right ventricular dysfunction in haemodialysis patients. Nephrol Dial Transplant 2021; 36:536.</a></li></ol></div><div id="topicVersionRevision">Topic 3462 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27470455" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : High-Output Heart Failure: A 15-Year Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36273803" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical outcomes and 30-day readmissions associated with high-output heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34944619" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Effects of Renal Denervation on the Enhanced Renal Vascular Responsiveness to Angiotensin II in High-Output Heart Failure: Angiotensin II Receptor Binding Assessment and Functional Studies in Ren-2 Transgenic Hypertensive Rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33307852" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Inhibition of Brainstem Endoplasmic Reticulum Stress Rescues Cardiorespiratory Dysfunction in High Output Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27470456" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : High-output heart failure revisted</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34353268" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : High-output Cardiac Failure: A Forgotten Phenotype in Clinical Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11242561" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : High Output Cardiac Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26290533" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Diet-induced obesity promotes altered remodeling and exacerbated cardiac hypertrophy following pressure overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29632154" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35880317" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30097335" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Association of body mass index and diastolic function in metabolically healthy obese with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33847141" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cardiac Morphology, Function, and Hemodynamics in Patients With Morbid Obesity and Nonalcoholic Steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33776013" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : High-output Heart Failure Caused by a Tumor-related Arteriovenous Fistula: A Case Report and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8672036" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Symptomatic intrarenal arteriovenous fistula detected 25 years after percutaneous renal biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11210999" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Congestive heart failure in a hypertensive patient (don't forget the stethoscope).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34647110" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Post-Traumatic Arteriovenous Fistulas Leading to Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33002586" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A systematic review and individual patient data meta-analysis of heart failure as a rare complication of traumatic arteriovenous fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11452347" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Aortocava fistula: experience with five patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23357664" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : High-output heart failure resulting from chronic aortocaval fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23217335" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : High-output heart failure: how to define it, when to treat it, and how to treat it.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25676293" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cardiac safety in vascular access surgery and maintenance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30350874" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cardiorenal syndrome in renal transplant recipients - It's the fistula at fault: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37004865" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : High-Output Heart Failure, Pulmonary Hypertension and Right Ventricular Failure in Patients With Arteriovenous Fistulas: A Call to Action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29886220" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Removal of Noninfected Arteriovenous Fistulae after Kidney Transplantation is a Safe and Beneficial Management Strategy for Unused Dialysis Access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37455468" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Long-Term Safety, Efficacy, Indications, and Criteria of Arteriovenous Fistula Ligation Following Kidney Transplant: A Patient-Driven Approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37086822" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effect of proximal artery restriction on flow reduction and cardiac function in hemodialysis patients with high-flow arteriovenous fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30007907" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Two cases of high-output heart failure as initial presentation of iliac arteriovenous fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7750353" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : High-output congestive heart failure following transjugular intrahepatic portal-systemic shunting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8944572" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18617281" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Incidence and outcome of femoral vascular complications among 18,165 patients undergoing cardiac catheterisation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12106934" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Incidence and clinical outcome of iatrogenic femoral arteriovenous fistulas: implications for risk stratification and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24709170" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Safety and feasibility of transulnar versus transradial artery approach for coronary catheterization in non-selective patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26124493" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Vascular Complications Following Transradial and Transulnar Coronary Angiography in 1600 Consecutive Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34317549" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Iatrogenic Arteriovenous Fistula Following Femoral Access Precipitating High-Output Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18269308" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Morbidity and mortality associated with Paget's disease of bone: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18297538" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2368788" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prevalence and clinical characteristics of a high cardiac output state in patients with multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9443728" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Arteriovenous shunting in patients with multiple myeloma and high-output failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10728441" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Assessment of cardiac function by echocardiography in Paget's disease of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/177939" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hyperdynamic heart failure due to A-V fistula associated with Wilms' tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24262803" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Digging deep: high output heart failure in renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37462043" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Case of High Output Heart Failure Caused by Renal Clear Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37216928" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : High cardiac output state due to pelvic arterio-venous shunt: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25195565" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Giant chorioangiomas: perinatal outcomes and techniques in fetoscopic devascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1259580" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Congenital arteriovenous anomalies of the limbs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23432737" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Congestive heart failure with diffuse neonatal hemangiomatosis--case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27789620" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Scalp congenital hemangioma with associated high-output cardiac failure in a premature infant: Case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9700146" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pulmonary arteriovenous malformations. A state of the art review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10501873" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pulmonary arteriovenous fistula: presentation, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6846129" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Osler-Weber-Rendu disease with multiple intrahepatic arteriovenous fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23312966" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Hereditary hemorrhagic telangiectasia, liver vascular malformations and cardiac consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27116331" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Reported cardiac phenotypes in hereditary hemorrhagic telangiectasia emphasize burdens from arrhythmias, anemia and its treatments, but suggest reduced rates of myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29794143" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37448947" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hereditary hemorrhagic telangiectasia in a 42-year-old Ethiopian man presenting with severe anemia and high-output heart failure: A case report with literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34917969" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Severe Hypoxemia Caused by High-Output Heart Failure and Pulmonary Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3618503" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Severe congestive heart failure in newborns due to giant cutaneous hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23025620" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Congenital cutaneous hemangioma causing cardiac failure: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10642962" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Successful transcutaneous arterial embolization of a giant hemangioma associated with high-output cardiac failure and Kasabach-Merritt syndrome in a neonate: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25516210" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Large multifocal cutaneous hemangioma along lines of Blaschko with cardiac failure treated with propranolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27686680" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effect of ventriculo-arterial coupling on transplant outcomes in cirrhotics: Analysis of pressure-volume curve relations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19376404" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cardiac hemodynamic profiles and pro-B-type natriuretic Peptide in cirrhotic patients undergoing liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18812641" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pathophysiology of portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17383244" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cirrhotic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16843085" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Water and sodium retention in edematous disorders: role of vasopressin and aldosterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16412185" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Echocardiographic detection of intrapulmonary shunting in a patient with hepatopulmonary syndrome: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25267959" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Pathophysiological and clinical approach to cirrhotic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7504425" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Metastatic carcinoid disease presenting solely as high-output heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12074037" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cardiovascular abnormalities in patients with a carcinoid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7985722" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Thyrotoxicosis-induced congestive heart failure in an urban hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11172193" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Thyroid hormone and the cardiovascular system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/85409" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Echocardiographic LV function in thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12556677" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Hyperthyroidism: a "curable" cause of congestive heart failure--three case reports and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13277087" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The hemodynamic and metabolic interrelationships in the activity of epinephrine, norepinephrine and the thyroid hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4792097" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Action of thyroid hormone on the transmembrane potentials from sinoatrial node cells and atrial muscle cells in isolated atria of rabbits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4272400" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Effect of thyroxine on ventricular myocardial contractility and ATPase activity in guinea pigs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17005710" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22956554" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Mechanisms in endocrinology: Heart failure and thyroid dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17848839" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Early abnormalities of left ventricular myocardial characteristics associated with subclinical hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7121544" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Abnormal left ventricular function in hyperthyroidism: evidence for a possible reversible cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6218743" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Cardiac performance in thyrotoxicosis: analysis of 10 untreated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12165109" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Cardiovascular hemodynamics and exercise tolerance in thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28025026" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Hyperdynamic Right Heart Function in Graves' Hyperthyroidism Measured by Echocardiography Normalises on Restoration of Euthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30139580" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Acute Right Ventricular Heart Failure: An Uncommon Case of Thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24966063" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Understanding cardiac failure in sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24351526" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Characterization of cardiac dysfunction in sepsis: an ongoing challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17698745" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Sepsis and the heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27529477" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Nitric Oxide Synthase 1 Modulates Basal andβ-Adrenergic-Stimulated Contractility by Rapid and Reversible Redox-Dependent S-Nitrosylation of the Heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5912298" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Hemodynamic studies in beriberi heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2649530" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The challenge of cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7342167" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The haemodynamic, histopathological and hormonal features of alcoholic cardiac beriberi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21838901" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Cardiovascular magnetic resonance in wet beriberi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24811895" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Thiamin deficiency and heart failure: the current knowledge and gaps in literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29489643" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Wet beriberi with multiple organ failure remarkably reversed by thiamine administration: A case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37051632" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Pulmonary artery catheter usage in diagnosis of Shoshin beriberi presented with unexplained lactic acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24972804" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : GH and the cardiovascular system: an update on a topic at heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18852535" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12034409" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : High output heart failure in patients with newly diagnosed acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28733467" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24531087" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Refractory high output heart failure in a patient with primary mitochondrial respiratory chain disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8012076" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : High-output heart failure in mitochondrial myopathy: a fulminant form with severe lactic acidosis and rhabdomyolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16103481" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : High-output heart failure associated with anagrelide therapy for essential thrombocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28343445" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : A Case of Anagrelide-Induced Nonischemic Cardiomyopathy in a Patient With Essential Thrombocythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17488690" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Heart disease in thalassemia intermedia: a review of the underlying pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23775258" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Cardiovascular function and treatment inβ-thalassemia major: a consensus statement from the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20630402" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Pathophysiology of anemia in heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16695220" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : THE CARDIAC OUTPUT IN PATIENTS WITH CHRONIC ANEMIA AS MEASURED BY THE TECHNIQUE OF RIGHT ATRIAL CATHETERIZATION.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11032352" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Pathophysiology of anaemia: focus on the heart and blood vessels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18990720" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : High output heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28863145" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Associations between endothelial dysfunction and clinical and laboratory parameters in children and adolescents with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6235732" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Cardiac size and function in children with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8487204" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Human circulatory and thermoregulatory adaptations with heat acclimation and exercise in a hot, dry environment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30700415" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9737227" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : High-output heart failure due to a renal arteriovenous fistula in a pregnant woman with suspected preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3405561" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : High-output heart failure due to hepatic arteriovenous fistula during pregnancy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3993716" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : An arteriovenous malformation in pregnancy: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3948561" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Hereditary telangiectasia and multiple pulmonary arteriovenous fistulas. Clinical deterioration during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34272792" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Cardiac output states in patients with severe functional tricuspid regurgitation: impact on treatment success and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32844287" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Portosystemic venous shunt in the patients with Fontan circulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33416919" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Systemic Artery Vasoconstrictor Therapy in Fontan Patients with High Cardiac Output-Heart Failure: A Single-Center Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33011786" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : High-flow arteriovenous fistula is not associated with increased extracellular volume or right ventricular dysfunction in haemodialysis patients.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
